Literature DB >> 1733942

Comparison of the enzymatic and biochemical properties of human insulin-degrading enzyme and Escherichia coli protease III.

L Ding1, A B Becker, A Suzuki, R A Roth.   

Abstract

The enzymatic and biochemical properties of human insulin-degrading enzyme and Escherichia coli protease III have been compared. Both enzymes were found to degrade insulin in such a way that its receptor binding activity was rapidly lost but its precipitability in trichloracetic acid was only slightly decreased. Both enzymes were also found to be inhibited by chelating agents. The bacterial enzyme, which could be purified in large amounts, was found to contain 0.6 mol of zinc per mol of enzyme but no detectable manganese. The mammalian enzyme but not the bacterial one was inhibited by a sulfhydryl alkylating agent. The two enzymes also differed in substrate specificity. The mammalian enzyme degraded insulin much better than insulin-like growth factor II, whereas the bacterial enzyme degraded them equally. The mammalian enzyme could be labeled by cross-linking to insulin = bombyxin II much greater than insulin-like growth factor I and II much greater than relaxin, while the bacterial enzyme was labeled by insulin-like growth factor II greater than insulin = insulin-like growth factor I much greater than relaxin much greater than bombyxin. Finally, sucrose gradient centrifugation and cross-linking studies both in vitro and in vivo indicated that active human enzyme partially existed as a homo- or heterodimer, whereas the bacterial enzyme was active as a monomer.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1733942

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  An unusual active site identified in a family of zinc metalloendopeptidases.

Authors:  A B Becker; R A Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

2.  Yeast Ste23p shares functional similarities with mammalian insulin-degrading enzymes.

Authors:  Benjamin J Alper; Jarrad W Rowse; Walter K Schmidt
Journal:  Yeast       Date:  2009-11       Impact factor: 3.239

3.  Characterization of the bacterial metalloendopeptidase pitrilysin by use of a continuous fluorescence assay.

Authors:  A Anastasi; C G Knight; A J Barrett
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

Review 4.  The mitochondrial processing peptidase: function and specificity.

Authors:  P Luciano; V Géli
Journal:  Experientia       Date:  1996-12-15

5.  Identification of glutamate-169 as the third zinc-binding residue in proteinase III, a member of the family of insulin-degrading enzymes.

Authors:  A B Becker; R A Roth
Journal:  Biochem J       Date:  1993-05-15       Impact factor: 3.857

6.  The characterization of endosomal insulin degradation intermediates and their sequence of production.

Authors:  P J Seabright; G D Smith
Journal:  Biochem J       Date:  1996-12-15       Impact factor: 3.857

7.  Molecular bases for the recognition of short peptide substrates and cysteine-directed modifications of human insulin-degrading enzyme.

Authors:  Enrico Malito; Luis A Ralat; Marika Manolopoulou; Julie L Tsay; Natasha L Wadlington; Wei-Jen Tang
Journal:  Biochemistry       Date:  2008-12-02       Impact factor: 3.162

8.  Molecular basis for the thiol sensitivity of insulin-degrading enzyme.

Authors:  Marie Neant-Fery; Rubén D Garcia-Ordoñez; Todd P Logan; Dennis J Selkoe; Lilin Li; Lael Reinstatler; Malcolm A Leissring
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-08       Impact factor: 11.205

9.  Degradation of relaxin family peptides by insulin-degrading enzyme.

Authors:  Robert G Bennett; Dean G Heimann; Frederick G Hamel
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

10.  Demonstration of specific insulin binding to cytosolic proteins in H35 hepatoma cells, rat liver and skeletal muscle.

Authors:  S Harada; R M Smith; J A Smith; N Shah; L Jarett
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.